Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.45
-0.4150-1.02%
Pre-market: 40.25-0.1950-0.48%04:22 EDT
Volume:1.39M
Turnover:56.59M
Market Cap:2.89B
PE:-8.67
High:41.32
Open:41.32
Low:39.86
Close:40.86
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:1.30
T/O Rate:2.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.77
PE(LYR):-8.67

Loading ...

Vera Therapeutics Announces Positive Origin Phase 3 Data for Atacicept in Iga Nephropathy Presented at Asn Kidney Week 2025 and Published in the New England Journal of Medicine

THOMSON REUTERS
·
Nov 06, 2025

Vera Therapeutics Reports Increased Losses Amid R&D Expansion

TIPRANKS
·
Nov 06, 2025

Vera Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

TIPRANKS
·
Nov 06, 2025

Vera Therapeutics reports Q3 EPS ($1.26), consensus ($1.13)

TIPRANKS
·
Nov 05, 2025

Vera Therapeutics Q3 EPS misses estimates

Reuters
·
Nov 05, 2025

Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate

Benzinga
·
Nov 05, 2025

BRIEF-Vera Therapeutics Q3 EPS USD -1.26 Vs. IBES Estimate USD -1.17

Reuters
·
Nov 05, 2025

Vera Therapeutics reports Q3 net loss of $80.3 million

Reuters
·
Nov 05, 2025

Vera Therapeutics Inc: Potential U.S. Commercial Launch of Atacicept in 2026

THOMSON REUTERS
·
Nov 05, 2025

Vera Therapeutics Advances IgAN Treatment with Atacicept Study

TIPRANKS
·
Oct 28, 2025

Vera Therapeutics to Present ORIGIN Phase 3 Atacicept Data for IgA Nephropathy at ASN Kidney Week 2025

Reuters
·
Oct 22, 2025

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

GlobeNewswire
·
Oct 22, 2025

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

GlobeNewswire
·
Oct 17, 2025

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market

Benzinga_recent_news
·
Oct 17, 2025

Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says

MT Newswires Live
·
Oct 17, 2025

BofA Securities Initiates Coverage on Vera Therapeutics With Buy Rating, $31 Price Target

MT Newswires Live
·
Oct 16, 2025

Vera Therapeutics Initiated at Buy by B of A Securities

Dow Jones
·
Oct 16, 2025

Vera Therapeutics initiated with a Buy at BofA

TIPRANKS
·
Oct 16, 2025

Cantor Fitzgerald Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Oct 14, 2025

Vera Therapeutics Announces New Inducement Compensation Plan for Twenty One Employees

Reuters
·
Oct 11, 2025